PA
RYTM icon

Perceptive Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Perceptive Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287M Buy
2,586,295
+212,500
+9% +$19.2M 4.31% 5
2026
Q1 		$206M Sell
2,373,795
-172,596
-7% -$16.8M 4.03% 6
2025
Q4 		$273M Buy
2,546,391
+107,422
+4% +$11.4M 4.86% 3
2025
Q3 		$288M Buy
2,438,969
+20,670
+0.9% +$1.92M 8.33% 1
2025
Q2 		$153M Sell
2,418,299
-130,146
-5% -$7.97M 5.67% 4
2025
Q1 		$135M Sell
2,548,445
-1,132,028
-31% -$62.8M 4.77% 5
2024
Q4 		$206M Buy
3,680,473
+120,259
+3% +$6.64M 5.68% 4
2024
Q3 		$187M Buy
3,560,214
+113,635
+3% +$5.44M 3.95% 6
2024
Q2 		$142M Buy
3,446,579
+178,000
+5% +$7.11M 3.41% 6
2024
Q1 		$142M Buy
3,268,579
+1,114,469
+52% +$48.8M 2.48% 8
2023
Q4 		$99M Buy
2,154,110
+1,773,282
+466% +$55.9M 2.21% 8
2023
Q3 		$8.73M Buy
+380,828
New +$8.53M 0.29% 62
2020
Q2 		– Sell
-170,859
Closed -$2.6M – 135
2020
Q1 		$2.6M Hold
170,859
– – 0.07% 89
2019
Q4 		$3.92M Buy
+170,859
New +$3.8M 0.08% 84
2019
Q3 		– Sell
-262,970
Closed -$5.79M – 119
2019
Q2 		$5.79M Sell
262,970
-240,000
-48% -$6.06M 0.13% 78
2019
Q1 		$13.8M Sell
502,970
-6,216
-1% -$179K 0.39% 51
2018
Q4 		$13.8M Sell
509,186
-155,000
-23% -$4.28M 0.52% 43
2018
Q3 		$19.4M Sell
664,186
-136,500
-17% -$4.31M 0.52% 43
2018
Q2 		$25M Buy
800,686
+208,400
+35% +$5.7M 0.66% 41
2018
Q1 		$11.8M Sell
592,286
-152,849
-21% -$4.06M 0.33% 57
2017
Q4 		$21.7M Buy
+745,135
New +$19.7M 0.72% 36

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Perceptive Advisors's RYTM Position: Q2 2026 in Review

Perceptive Advisors increased its Rhythm Pharmaceuticals (RYTM) stake by 9% in Q2 2026, buying an estimated $19.2M and bringing the position to 2,586,295 shares worth $287M. The position accounts for 4.31% of the portfolio, ranked #5.

Perceptive Advisors first reported a position in RYTM in Q4 2017 and has held it in 21 quarters since. The position peaked at $288M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Perceptive Advisors held 2,586,295 shares of Rhythm Pharmaceuticals worth $287M as of Q2 2026.
  • Perceptive Advisors bought 212,500 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $19.2M.
  • Rhythm Pharmaceuticals made up 4.31% of Perceptive Advisors's portfolio in Q2 2026, its #5 holding.
  • Perceptive Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 21 quarters since.
  • Perceptive Advisors's Rhythm Pharmaceuticals position peaked at $288M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.